

ALN-4915 Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	To be disclosed
MoA	To be disclosed
Route of Administration	Subcutaneous ¹

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting 		
Safety, Tolerability, PK, and PD of ALN-4915 Adult Healthy Volunteers ¹	ALN-4915; placebo	Frequency of AEs up to Month 12

The safety and efficacy of ALN-4915 has not been established by any health authority.
AE, adverse event; MoA, mechanism of action; PD, pharmacodynamics; PK, pharmacokinetics; RNA, ribonucleic acid; RNAi, RNA interference. 1. ClinicalTrials.gov. 2026.
<https://clinicaltrials.gov/study/NCT07535606> (Accessed May 4, 2026).